Radleys

DIREVO and Pfizer Collaborate on Therapeutic Proteases

Date Posted: Tuesday, November 13, 2007

Print Email to a friend

DIREVO Biotech AG has announced the signing of a collaboration agreement with Pfizer, Inc., New York, to develop therapeutic proteases for different targets as potential treatments for various diseases. Direvo will apply its protein-engineering capabilities to create novel proteases with engineered specificity for these targets.

Under the terms of the agreement, Direvo will use its protein engineering expertise to discover and optimize preclinical candidates. Pfizer will then be responsible for the development and marketing of the respective compounds.

Direvo will receive payments upon reaching certain research and development milestones as well as royalties for any resulting product that reaches the market.

"We are proud that Pfizer has chosen Direvo as a partner for development of an exciting novel class of protein drugs," said Dr. Thomas von Rueden, CEO of Direvo.

"This collaboration is an important commercial validation for Direvo's proven world-class technology-platform for the generation of optimized proteases with engineered specificity for various indications" he added.

Further Information: http://www.direvo.com



Related news from our archive

Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
Companies will jointly conduct Phase III development and commercialization of DGAT-1 inhibitor compounds.

Pfizer and Bristol-Myers Squibb Finalize Worldwide Collaboration on Metabolic Disorders Program
Companies will jointly conduct Phase III development and commercialization of DGAT-1 inhibitor compounds.

Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists
Pfizer will continue to fund the research and preclinical development efforts at Renovis through June 30, 2008, to advance small molecule VR1 antagonists toward clinical development.